REDUCE试验:周围神经地塞米松对头皮神经阻滞缓解开颅术后疼痛的影响——一项随机对照试验的研究方案
REDUCE试验为前瞻性、单中心、平行组随机对照试验,纳入156例择期全麻开颅手术成人,随机分为对照组(n=78)和DEX4mg组(n=78)。对照组行0.5%布比卡因加1:200,000肾上腺素生理盐水头皮神经阻滞,DEX4mg组在相同布比卡因基础上加4 mg地塞米松。主要结局为镇痛持续时间,即从实施阻滞至首次请求镇痛药的时间。该试验旨在评估无围术期糖皮质激素背景下单次地塞米松作为头皮神经阻滞佐剂缓解开颅术后疼痛的镇痛效果。
要点
- 开颅术后前2天疼痛常见,主要源于颅周肌肉和头皮软组织。
- 头皮神经阻滞似可提供有效、安全但短暂的术后镇痛,似不能满足开颅手术需求。
- REDUCE试验评估无围术期糖皮质激素背景下单次地塞米松作为头皮神经阻滞佐剂的镇痛效果。
核心结论
- REDUCE试验旨在进一步评估无围术期糖皮质激素背景下单次地塞米松作为头皮神经阻滞佐剂缓解开颅术后疼痛的镇痛效果。
研究设计与样本
- REDUCE试验为前瞻性、单中心、平行组随机对照试验,共纳入156例择期全麻开颅手术成人。
- 患者随机分为对照组(n=78)和DEX4mg组(n=78)。
- 对照组行0.5%布比卡因加1:200,000肾上腺素生理盐水头皮神经阻滞;DEX4mg组行0.5%布比卡因加4 mg地塞米松及1:200,000肾上腺素头皮神经阻滞。
- 主要结局为镇痛持续时间,定义为从实施阻滞至首次请求镇痛药的时间。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pain is common in the first 2 days after major craniotomy. Inadequate analgesia may lead to an increased risk of postoperative complications. Most pain following craniotomy arises from the pericranial muscles and soft tissues of the scalp. Scalp nerve blocks with local anesthesia seem to provide effective, safe, however, transient postoperative analgesia which does not seem to meet the requirements of craniotomy. Currently, peripheral dexamethasone has been observed to significantly prolong the duration of analgesia of nerve blocks (e.g., saphenous nerve block, adductor canal block, thoracic paravertebral block, brachial plexus nerve block). On the contrary, a study reported that perineural dexamethasone did not appear to prolong the analgesic time after supratentorial craniotomy. However, all patients in this study were given 24 mg of oral or intravenous dexamethasone regularly for at least 7 days during the perioperative period, which possibly masked the role of single local low doses of perineural dexamethasone. Therefore, the analgesic effect of single dexamethasone for scalp nerve blocks without the background of perioperative glucocorticoid deserves further clarification. METHODS: The REDUCE trial is a prospective, single-center, parallel-group randomized controlled trial involving a total of 156 adults scheduled for elective craniotomy with general anesthesia. Patients will be randomly divided among two groups: the control group (n = 78) will receive scalp nerve blocks with 0.5% bupivacaine, plus normal saline with epinephrine at 1:200,000; the DEX4mg group (n = 78) will receive scalp nerve blocks with 0.5% bupivacaine, plus 4 mg dexamethasone with epinephrine at 1:200,000. The primary outcome will be the duration of analgesia, defined as the time between the performance of the block and the first analgesic request. DISCUSSION: The REDUCE trial aims to further assess the analgesic effect of single dexamethasone as an adjuvant to scalp nerve blocks for relief of postcraniotomy pain without the background of perioperative glucocorticoid. TRIAL REGISTRATION: ClinicalTrials.gov NCT04648358 . Registered on November 30, 2020.
引用
- Zhao C, Jia Z, Shrestha N, et al. REDUCE trial: the effects of perineural dexamethasone on scalp nerve blocks for relief of postcraniotomy pain-a study protocol for a randomized controlled trial. Trials. 2021. PMID: 34736497. doi:10.1186/s13063-021-05747-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。